Steven Henck

Steven Henck was appointed IDT Vice President, R&D in October 2021. Previously, since joining IDT in April 2019 Steven had served as Vice President of Molecular Biology Research and Development, providing oversight of R&D initiatives in the area of Genomics Analysis.

Steven has been leading the development of technologies for Next Generation Sequencing, NGS, since 1997 when he moved from Texas Instruments to CuraGen Corp. to develop micro-machined integrated circuits for DNA sequencing. There he also helped establish 454 Life Sciences which created the first commercial NGS sequencing system, and several high-throughput technology platforms for drug discovery and development. Steven was a co-founder and President of an alternative biofuel company, Arbor Fuel Inc. In 2010 he joined Roche Diagnostics to lead their nanopore-based NGS diagnostics platform development and later led the identification and acquisition of multiple technologies and NGS companies. At IDT, he has been leading the development of library prep technologies, assays, and enzymes for NGS since 2019.

Steven holds his Bachelor of Science from Eastern Nazarene College, and his master’s degree and PhD in Chemistry from Princeton University.